Skip to main content

Table 3 Evening pre-dose FEV1 on Day 28 of treatment and improvement from period baseline for each treatment regimen (all placebo treatments were pooled for these analyses)

From: Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma

  Placebo FF 200 μg OD FF 100 μg BD FP 200 μg OD FP 100 μg BD
Number of patients 187 140 142 42 43
LS mean, ml (SE) 2605
(43.4)
2714
(44.4)
2703
(44.3)
2693
(53.5)
2737
(53.3)
LS mean change from period baseline, ml (SE) 112
(18.6)
221
(20.9)
210
(20.7)
199
(36.5)
244
(36.1)
LS mean difference
(active-placebo), ml
(95% CI)
NA 108
(64-153);
p < 0.001
98
(54-142);
p < 0.001
87
(14-161);
p = 0.020
132
(59-205);
p < 0.001
LS mean difference
(FF 200 μg OD-FF 100 μg BD), ml
(95% CI)
NA 11
(-35-56);
p = 0.641
NA NA NA
  1. Absolute values and all differences are LS means, with 95% CI for non-inferiority and p values for superiority analysis for all comparisons between treatments. Data shown are for the ITT population.
  2. BD = twice daily; CI = confidence interval; FF = fluticasone furoate;
  3. FP = fluticasone propionate; LS = least square, NA = not applicable; OD = once daily; SE = standard error